A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors

NCT02791334 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

164

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor
Microsatellite Instability-High (MSI-H) Solid Tumors
Cutaneous Melanoma
Pancreatic Cancer
Breast Cancer (HR+HER2-)

Interventions

DRUG: LY3300054
DRUG: Ramucirumab
DRUG: Abemaciclib
DRUG: Merestinib
DRUG: LY3321367

Sponsor

Eli Lilly and Company